Ibrutinib/rituximab versus placebo/rituximab in Waldenstrom's Macroglobulinemia (WM): results of a randomized phase 3 trial

Christian Buske; Alessandra Tedeschi; Judith Trotman; Ramón García‐Sánz; D. Blair Macdonald; V. Leblond; Beatrice Mahé; Charles Herbaux; Constantine S. Tam; Maria Eduarda Palomba; J. Matouš; Chaim Shustik; Efstathios Kastritis; SP Treon; J Li; Zeena Salman; Thorsten Graef; Meletios A Dimopoulos

Related publications

Article2018

Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenström’s Macroglobulinemia (iNNOVATE)

M. Lia Palomba, Meletios A Dimopoulos, Alessandra Tedeschi, Judith Trotman, Ramón García‐Sánz, David MacDonald, Véronique Leblond, Beatrice Mahé, Charles Herbaux, Constantine S. Tam, Jeffrey Matous, Chaim Shustik, Efstathios Kastritis, Steven P. Treon, Jianling Li, Zeena Salman, Thorsten Graef, Christian Buske

Article2018

Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia.

Meletios A Dimopoulos, Alessandra Tedeschi, Judith Trotman, Ramón García‐Sánz, David MacDonald, Véronique Leblond, Beatrice Mahé, Charles Herbaux, Constantine S. Tam, Maria Lia Palomba, Jeffrey Matous, Chaim Shustik, Efstathios Kastritis, Steven P. Treon, Jianling Li, Zeena Salman, Thorsten Graef, Christian Buske

Article2020

ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM).

Constantine S. Tam, Stephen Opat, Shirley D’Sa, Wojciech Jurczak, Hui‐Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Alessandra Tedeschi, Jorge J. Castillo, Tanya Siddiqi, Christian Buske, Véronique Leblond, Wai‐Yee Chan, Jingjing Schneider, Sunhee Ro, Aileen Cohen, Jane Huang, Meletios A Dimopoulos

Article2018

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

Meletios A Dimopoulos, Alessandra Tedeschi, Judith Trotman, Ramón García‐Sánz, D. Blair Macdonald, Véronique Leblond, Beatrice Mahé, Charles Herbaux, Constantine S. Tam, Lorella Orsucci, M. Lia Palomba, Jeffrey Matous, Chaim Shustik, Efstathios Kastritis, Steven P. Treon, Jianling Li, Zeena Salman, Thorsten Graef, Christian Buske

Article2022

ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM).

Constantine S. Tam, Ramón García‐Sánz, Stephen Opat, Shirley D’Sa, Wojciech Jurczak, Hui‐Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Alessandra Tedeschi, Jorge J. Castillo, Tanya Siddiqi, Christian Buske, Véronique Leblond, Wai‐Yee Chan, Jingjing Schneider, Aileen Cohen, Jane Huang, Meletios A Dimopoulos

Ibrutinib/rituximab versus placebo/rituximab in Waldenstrom's Macroglobulinemia (WM): results of a randomized phase 3 trial

Discussion(0)

Related publications

Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenström’s Macroglobulinemia (iNNOVATE)

Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia.

ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM).

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM).